EQS-News: Marinomed Biotech AG: Annual General Meeting elects Dr. Eva Hofstädter-Thalmann as a new member of the Supervisory Board
EQS-News: Marinomed Biotech AG / Key word(s): AGM/EGM
Marinomed Biotech AG: Annual General Meeting elects Dr. Eva
Hofstädter-Thalmann as a new member of the Supervisory Board
21.06.2023 / 17:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
Marinomed Biotech AG: Annual General Meeting elects Dr. Eva
Hofstädter-Thalmann as a new member of the Supervisory Board
• Industry expert Dr. Eva Hofstädter-Thalmann complements high-profile
Supervisory Board
• Dr. Simon Nebel and Mag. Brigitte Ederer reappointed
• Current female representation on Supervisory Board reaches at 60%
Korneuburg, Austria, 21 June 2023 – At today’s 6^th Annual General Meeting
of Marinomed Biotech AG (VSE:MARI), Dr. Eva Hofstädter-Thalmann was newly
elected to the Company’s Supervisory Board. The Chairman of the
Supervisory Board, Dr. Simon Nebel, as well as Mag. Brigitte Ederer, whose
mandates ended rotationally, were reappointed for four years. Ute Lassnig
and Dr. Gernot Hofer did not stand for re-election, thus the Supervisory
Board of Marinomed Biotech AG now consists of Dr. Simon Nebel, Brigitte
Ederer, Dr. Elisabeth Lackner, Ulrich Kinzel and Dr. Eva
Hofstädter-Thalmann. As a result, the female representation on Marinomed’s
Supervisory Board now stands at 60%.
Dr. Eva Hofstädter-Thalmann, who holds a doctorate in biochemistry, spent
more than 30 years in the pharmaceutical industry, working for Johnson &
Johnson and Janssen in several commercial and medical affairs leadership
positions with an increasing global responsibility. Her tasks extended to
the areas of oncology, hematology and virology. In addition to her
professional activities, she has been involved in medical education in the
pharmaceutical industry for many years. Currently, she is the President of
the Global Alliance of Medical Education (GAME) and member of the Board of
Directors of the Journal of European Continuing Medical Education (JECME).
Eva Hofstädter-Thalmann has been working as an independent consultant in
healthcare with a focus on strategic stakeholder management for the
pharmaceutical industry as well as for international medical companies
since the beginning of 2023.
Dr. Simon Nebel, Chairman of the Supervisory Board: „We are very pleased
to welcome Eva Hofstädter-Thalmann, a renowned and globally well-connected
pharmaceutical expert to Marinomed’s Supervisory Board. I am very much
looking forward to our cooperation. At the same time, I would like to
express my appreciation to Ute Lassnig and Gernot Hofer for their valuable
commitment over the past years.“
At the 6^th Annual General Meeting, the Management Board was also
authorized to increase the Company’s share capital by up to EUR 759,583 by
June 20, 2028, with the option of partial or total exclusion of
subscription rights („Authorized Capital 2023”).
All further resolutions proposed by the Management Board and the
Supervisory Board were approved with a large majority.
Further information on the Annual General Meeting including the voting
results, the Management Board presentation and the CVs of the Supervisory
Board members can be found in the investors section of the corporate
website at:
[1] https://www.marinomed.com/en/investors-esg/annual-general-meeting.
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline and globally marketed therapeutics. The
Company develops innovative patent-protected products in the therapeutic
areas immunology and virology based on the platform Marinosolv® and the
virus-blocking activity of iota-carrageenan. The Marinosolv® technology
improves the solubility and bioavailability of hardly soluble compounds
and is used to develop new therapeutics for autoreactive immune disorders.
The virology segment includes Carragelose®-based over-the-counter (OTC)
products to prevent and treat respiratory viral infections that are
partnered in more than 40 countries. The Company is headquartered in
Korneuburg, Austria, and is listed on the prime market of the Vienna Stock
Exchange (VSE:MARI). For further information, please visit:
https://www.marinomed.com.
For further inquiries contact:
Marinomed Biotech AG International Media Contact
PR: Lucia Ziegler Metrum Communications: Roland Mayrl
T: +43 2262 90300 158 T: +43 664 6126228
E-Mail: [2]pr@marinomed.com E-Mail: [4]marinomed@metrum.at
IR: Stephanie Kniep
T: +43 2262 90300 226
E-Mail: [3]ir@marinomed.com
Disclaimer
This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are
subject to risks, uncertainties and assumptions that could cause actual
results, performance or events to differ materially from those described
in, or expressed or implied by, such statements. The current views,
expectations and projections of the management of Marinomed Biotech AG may
be identified by the context of such statements or words such as
“anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project”
and “target”. Forward-looking statements are only valid as of the date
they are made and Marinomed Biotech AG does not assume any obligation to
update, review or revise any forward-looking statements contained in this
press release whether as a result of new information, future developments
or otherwise. Marinomed, Marinosolv® and Carragelose® are registered
trademarks of Marinomed Biotech AG. These trademarks may be owned or
licensed in select locations only.
══════════════════════════════════════════════════════════════════════════
21.06.2023 CET/CEST This Corporate News was distributed by EQS Group AG.
www.eqs.com
══════════════════════════════════════════════════════════════════════════
Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Austria
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
ISIN: ATMARINOMED6
WKN: A2N9MM
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 1662565
End of News EQS News Service
1662565 21.06.2023 CET/CEST
References
Visible links
1. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=cfb52b1a8774a6260659353b50085997&application_id=1662565&site_id=apa_ots_austria&application_name=news
2. pr@marinomed.com
3. ir@marinomed.com
4. marinomed@metrum.at
OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender